Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach

Cruz, Rossilene Conceição da Silva; Bührer-Sékula, Samira; Penna, Gerson Oliveira; Moraes, Maria Elisabete Amaral de; Gonçalves, Heitor de Sá; Stefani, Mariane Martins de Araújo; Penna, Maria Lúcia Fernandes; Pontes, Maria Araci de Andrade; Talhari, Sinésio.
An. bras. dermatol ; 93(3): 377-384, May-June 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-949891

Documentos relacionados

  1. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
  2. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
  3. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
  4. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
  5. Clofazimine: new products. Major antileprous drug.
  6. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
  7. Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study.
  8. Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
  9. Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital.
  10. Single-Dose Rifapentine in Household Contacts of Patients with Leprosy.